Journal ArticleDOI
Exercise testing in patients with chest pain to sumatriptan
Jan Paul Ottervanger,Jan C.A. Hoorntje,Hans A. Valkenburg,Diederick E. Grobbee,Bruno H. Stricker +4 more
Reads0
Chats0
TLDR
The prevalence of abnormal exercise tests in patients with sumatriptan-induced chest pain is low, and not statistically different from patients without chest pain after intake of sumatripan, according to a case-control study.Abstract:
Objectives: In order to assess whether chest pain attributed to sumatriptan is associated with abnormalities on cardiac exercise testing, we performed a case-control study. Subjects: Cases were selected as consumers of sumatriptan who reported sumatriptan associated chest pain. A reference group was selected randomly from consumers of sumatriptan with the same GP as the case, who reported no chest pain after use of sumatriptan. If possible, controls were matched for age (within 5-year groups) and gender. Outcomes: In a total of 74 cases and 55 controls symptom-limited exercise tests were performed. Besides a small difference in age, there were no differences in basic characteristics between cases and controls. Three cases had ST-depression on ECG during exercise. However, none of the variables measured during exercise testing differed significantly between cases and controls. Conclusions: The prevalence of abnormal exercise tests in patients with sumatriptan-induced chest pain is low, and not statistically different from patients without chest pain after intake of sumatriptan. Routine performance of exercise testing in patients with sumatriptan-associated chest pain is not recommended.read more
Citations
More filters
Journal ArticleDOI
The pharmacology of headache
TL;DR: The pharmacology of the head pain systems, as they are known and as they might evolve, are explored in the context of both, the anatomy and physiology of trigeminovascular nociception and in the contexts of clinical questions, such as those of efficacy, headache recurrence and adverse events.
Journal ArticleDOI
Evaluating the safety and tolerability profile of acute treatments for migraine.
TL;DR: Triptans as a class are contraindicated in patients with established or clinically suspected cardiovascular disease, specifically ischemic heart disease and uncontrolled hypertension, and other adverse events, including the potential for drug-drug interactions, are less common.
Journal ArticleDOI
Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633.
R B McCall,R Huff,C L Chio,R TenBrink,C L Bergh,Michael D. Ennis,N B Ghazal,Robert L Hoffman,K Meisheri,N R Higdon,E Hall +10 more
TL;DR: The present study describes the preclinical pharmacology of a highly selective 5-HT1Dreceptor agonist PNU-142633, which was equally effective and a half-log more potent than sumatriptan in preventing plasma protein extravasation induced by electrical stimulation of the trigeminal ganglion.
Journal ArticleDOI
Effect of high-dose intravenous eletriptan on coronary artery diameter
TL;DR: The results confirm that eletriptan has a broad cardiovascular safety margin, with plasma concentrations comparable to three to five times the Cmax of an oral 80-mg dose associated with modest vasoconstriction equivalent to standard therapeutic doses of sumatriptan.
Journal ArticleDOI
Enhanced Contraction to 5-Hydroxytryptamine Is Not Due to “Unmasking” of 5-Hydroxytryptamine1B Receptors in the Mesenteric Artery of the Deoxycorticosterone Acetate–Salt Rat
TL;DR: The response of superior mesenteric arteries from normotensive sham and hypertensive deoxycorticosterone acetate (DOCA)–salt rats is examined to support the conclusions that 5-HT1B receptors mediate contraction in mesenteri arteries from hypertensive rats and that this enhanced response to 5- HT is not due to membrane depolarization alone.
References
More filters
Journal ArticleDOI
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
David S. Celermajer,Keld E. Sørensen,V.M. Gooch,David Spiegelhalter,Owen Miller,Ian D. Sullivan,J.K. Lloyd,John E. Deanfield +7 more
TL;DR: Endothelial dysfunction is present in children and adults with risk factors for atherosclerosis, such as smoking and hypercholesterolaemia, before anatomical evidence of plaque formation in the arteries studied, suggesting this may be an important early event in atherogenesis.
Journal ArticleDOI
Systemic nature of endothelial dysfunction in atherosclerosis.
Todd J. Anderson,Marie D. Gerhard,Ian T. Meredith,Francois Charbonneau,Danielle Delagrange,Mark A. Creager,Andrew P. Selwyn,Peter Ganz +7 more
TL;DR: The hypothesis that endothelial dysfunction is a systemic process is explored, and new noninvasive methods of assessing endothelial function are discussed, as methods to assess this have not been readily available.
Journal ArticleDOI
Effect of Intracoronary Serotonin on Coronary Vessels in Patients with Stable Angina and Patients with Variant Angina
Eugene P. McFadden,J. Clarke,Graham J. Davies,Juan Carlos Kaski,Agha W. Haider,Attilio Maseri +5 more
TL;DR: It is suggested that serotonin, released after the intracoronary activation of platelets, may contribute to or cause myocardial ischemia in patients with coronary artery disease.
Journal ArticleDOI
Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation.
TL;DR: Sumatriptan, a SHT, receptor agonist administered by the subcutaneous route, causes a vasopressor response in the systemic and pulmonary arterial circulations and coronary artery vasoconstriction.
Journal ArticleDOI
The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine.
Peer Tfelt-Hansen,Patrick Henry,Laurence J Mulder,Rudy G Scheldewaert,Jean Schoenen,G Chazot +5 more
TL;DR: LAS+MTC was significantly more effective in the treatment of nausea than sumatriptan (p < 0.0001) and was better tolerated (adverse events in 18% and 28%, respectively, p = 0.05).